RXi, UMass to collaborate on ALS research

The Angel Fund, The ALS Therapy Alliance and Project ALS, three organizations dedicated to finding an ALS treatment, have come together to support a new collaboration. Dr. Robert Brown, a leading ALS researcher, and RXi Pharmaceuticals, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference, have received support for this collaboration. Dr. Brown is chairman of the Department of Neurology at the UMASS Medical School; he and his team will study the use of RXi’s self-delivering compounds as a potential ALS therapy.

Click here to read more.

Share this: